XORTX Therapeutics Inc.
XRTX.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.44% | -2.62% | |||
| Depreciation & Amortization | 6.52% | 6.15% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.56% | -12.72% | |||
| Operating Income | 30.56% | 12.72% | |||
| Income Before Tax | 9.50% | -2.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.50% | -2.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.50% | -2.72% | |||
| EBIT | 30.56% | 12.72% | |||
| EBITDA | 30.77% | 12.89% | |||
| EPS Basic | 29.45% | -1.34% | |||
| Normalized Basic EPS | 29.39% | -1.37% | |||
| EPS Diluted | 29.63% | 0.00% | |||
| Normalized Diluted EPS | 29.39% | -1.37% | |||
| Average Basic Shares Outstanding | 28.20% | 1.37% | |||
| Average Diluted Shares Outstanding | 28.20% | 1.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||